Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer

NCT00474916 is registered in ClinicalTrials.gov with DARA Therapeutics as lead sponsor.

NCT NCT00474916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00474916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer
Lead sponsor
DARA Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
April 30, 2009
Enrollment
19 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain